Innate PharmaIPHA -2.44%41 ROC (Joel Greenblatt) % is -1,196.15% as of Dec. 2025. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,324 Biotechnology companies, Innate Pharma ranks worse than 67.3% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Innate Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,196.15%.
The historical rank and industry rank for Innate Pharma's ROC (Joel Greenblatt) % or its related term are showing as below:
IPHA'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1027.23 Med: -253.17 Max: 169.7
Current: -1012.26
During the past 13 years, Innate Pharma's highest ROC (Joel Greenblatt) % was 169.70%. The lowest was -1027.23%. And the median was -253.17%.
IPHA's ROC (Joel Greenblatt) % is ranked worse than 67.3% of 1324
companies
in the Biotechnology industry
Industry Median: -297.06
vs IPHA: -1012.26
Innate Pharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -121.40% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Innate Pharma ROC (Joel Greenblatt) % Related Terms
Innate Pharma ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Innate Pharma's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPHA vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Innate Pharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Innate Pharma's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -1,196.15% mean?
Innate Pharma (IPHA) has a ROC (Joel Greenblatt) % of -1,196.15% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Innate Pharma and its competitors. According to the industry distribution chart, Innate Pharma ranks #891 out of 1324 companies in the Biotechnology industry, placing it in the top 67.3%.
Is Innate Pharma's ROC (Joel Greenblatt) % too high?
Innate Pharma's current ROC (Joel Greenblatt) % is -1,196.15%. Based on the distribution chart, Innate Pharma ranks #891 out of 1324 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #891 out of 1324 companies for ROC (Joel Greenblatt) %. This places Innate Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Innate Pharma and its competitors. Innate Pharma's current ROC (Joel Greenblatt) % is -1,196.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $1.80 — trading 1100% above its estimated fair value. The current ROC (Joel Greenblatt) % is -1,196.15%. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Innate Pharma (IPHA), the current ROC (Joel Greenblatt) % is -1,196.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.80 is trading 1100% above its estimated GF Value™ of $0.15.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
ROC (Joel Greenblatt) %: -1,196.15%
GF Value™: $0.15 vs. price of $1.80 (1100% above fair value)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
